Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. (Q48131663)
Jump to navigation
Jump to search
scientific article published on 20 January 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. |
scientific article published on 20 January 2015 |
Statements
1 reference
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. (English)
1 reference
Hans-Jürgen Möller
1 reference
Koen Demyttenaere
1 reference
Bengt Olausson
1 reference
Johan Szamosi
1 reference
Ellis Wilson
1 reference
David Hosford
1 reference
Geoffrey Dunbar
1 reference
Raj Tummala
1 reference
Hans Eriksson
1 reference
20 January 2015
1 reference
16
1 reference
7
1 reference
483-501
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference